NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 902.6 DKK | +2.01% |
|
+3.12% | +29.29% |
| Apr. 30 | FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications | MT |
| Apr. 30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
902.6
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +29.29% | 567B | |
| +34.00% | 664B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +13.79% | 234B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B | |
| -11.01% | 145B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk, Aspen Pharmacare Sign Insulin Production Deal for Africa
